Log in
OTCMKTS:NVZMY

NOVOZYMES A/S/S Stock Forecast, Price & News

$65.47
-0.19 (-0.29 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$65.03
Now: $65.47▼
$66.06
50-Day Range
$57.40
MA: $60.03▼
$65.98
52-Week Range
$37.99
Now: $65.47▼
$66.75
Volume11,668 shs
Average Volume41,979 shs
Market Capitalization$19.44 billion
P/E Ratio41.70
Dividend Yield0.79%
Beta0.61
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry. It also provides wastewater solutions, such as additives, biogas production, industrial bio cleaning, compound removal, odor control, and system start-up solutions; and textile solutions comprising bioscouring, bleach clean-up, desizing, denim finishing and abrasion, and biopolishing solutions. In addition, the company offers forest products that include bleach boosting, deinking, fiber modification, effluent control, pitch and stickies control, and starch modification products; and leather solutions, which comprise biopreparation, degreasing, and re-bating. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis; and rtrypsin for cell culture. Novozymes A/S has a strategic collaboration with Boehringer Ingelheim Animal Health for the research and development, production, marketing, and sale of a portfolio of probiotic products. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Read More
NOVOZYMES A/S/S logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 1.8Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.82 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorBasic Materials
Current SymbolOTCMKTS:NVZMY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.novozymes.com
Phone45-4446-0000

Debt

Debt-to-Equity Ratio0.37
Current Ratio1.53
Quick Ratio0.98

Price-To-Earnings

Trailing P/E Ratio41.70
Forward P/E Ratio41.70
P/E Growth39.79

Sales & Book Value

Annual Sales$2.16 billion
Price / Sales9.02
Cash Flow$1.59 per share
Price / Cash Flow41.18
Book Value$5.79 per share
Price / Book11.31

Profitability

EPS (Most Recent Fiscal Year)$1.65
Net Income$472.79 million
Net Margins20.73%
Return on Equity26.95%
Return on Assets14.77%

Miscellaneous

Employees6,125
Outstanding Shares297,000,000
Market Cap$19.44 billion
Next Earnings Date10/28/2020 (Estimated)
OptionableNot Optionable
$65.47
-0.19 (-0.29 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVZMY News and Ratings via Email

Sign-up to receive the latest news and ratings for NVZMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions

How has NOVOZYMES A/S/S's stock been impacted by Coronavirus (COVID-19)?

NOVOZYMES A/S/S's stock was trading at $45.0314 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVZMY stock has increased by 45.4% and is now trading at $65.47.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of NOVOZYMES A/S/S?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 5 sell ratings, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NOVOZYMES A/S/S.

When is NOVOZYMES A/S/S's next earnings date?

NOVOZYMES A/S/S is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for NOVOZYMES A/S/S.

How were NOVOZYMES A/S/S's earnings last quarter?

NOVOZYMES A/S/S (OTCMKTS:NVZMY) issued its quarterly earnings results on Tuesday, August, 11th. The biotechnology company reported $0.34 EPS for the quarter, missing the Zacks' consensus estimate of $0.35 by $0.01. The biotechnology company earned $494.34 million during the quarter, compared to the consensus estimate of $501.01 million. NOVOZYMES A/S/S had a return on equity of 26.95% and a net margin of 20.73%.
View NOVOZYMES A/S/S's earnings history.

How often does NOVOZYMES A/S/S pay dividends? What is the dividend yield for NOVOZYMES A/S/S?

NOVOZYMES A/S/S declared an annual dividend on Friday, January 24th. Stockholders of record on Friday, February 28th will be given a dividend of $0.517 per share on Tuesday, March 17th. This represents a dividend yield of 1.01%. The ex-dividend date of this dividend is Thursday, February 27th. This is an increase from NOVOZYMES A/S/S's previous annual dividend of $0.50.
View NOVOZYMES A/S/S's dividend history.

Are investors shorting NOVOZYMES A/S/S?

NOVOZYMES A/S/S saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,900 shares, an increase of 107.1% from the August 15th total of 1,400 shares. Based on an average trading volume of 22,300 shares, the short-interest ratio is presently 0.1 days.
View NOVOZYMES A/S/S's Short Interest.

Who are some of NOVOZYMES A/S/S's key competitors?

Some companies that are related to NOVOZYMES A/S/S include Biogen (BIIB), Seattle Genetics (SGEN), Moderna (MRNA), BioNTech (BNTX), argenx (ARGX), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Repligen (RGEN), Novavax (NVAX), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Crispr Therapeutics (CRSP) and Iovance Biotherapeutics (IOVA).
View all competitors.

Who are NOVOZYMES A/S/S's key executives?

NOVOZYMES A/S/S's management team includes the following people:
  • Mr. Peder Holk Nielsen, Pres & CEO (Age 63)
  • Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 44)
  • Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 59)
  • Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 56)
  • Mr. Anders Lund, Exec. VP of Household Care & Technical Industries (Age 46)

What is NOVOZYMES A/S/S's stock symbol?

NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of NOVOZYMES A/S/S?

Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NOVOZYMES A/S/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $65.47.

How big of a company is NOVOZYMES A/S/S?

NOVOZYMES A/S/S has a market capitalization of $19.44 billion and generates $2.16 billion in revenue each year. The biotechnology company earns $472.79 million in net income (profit) each year or $1.65 on an earnings per share basis. NOVOZYMES A/S/S employs 6,125 workers across the globe.

What is NOVOZYMES A/S/S's official website?

The official website for NOVOZYMES A/S/S is www.novozymes.com.

How can I contact NOVOZYMES A/S/S?

NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.